Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ligand Pharm
(NQ:
LGND
)
103.82
+0.20 (+0.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ligand Pharm
< Previous
1
2
3
4
5
6
Next >
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Making Surprising Moves in Tuesday Session
February 27, 2024
Via
Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 27, 2024
Via
Benzinga
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Ligand Pharmaceuticals's Earnings: A Preview
February 26, 2024
Via
Benzinga
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
February 22, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Where Ligand Pharmaceuticals Stands With Analysts
September 19, 2023
Via
Benzinga
Analyst Expectations for Ligand Pharmaceuticals's Future
August 23, 2023
Via
Benzinga
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
February 16, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 13, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
January 05, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
December 12, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
December 06, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
December 01, 2023
From
Palvella Therapeutics
Via
GlobeNewswire
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
November 28, 2023
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent
Via
Benzinga
Ligand Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
November 01, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand To Report Third Quarter 2023 Financial Results On November 8
October 25, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 18, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
September 27, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Appoints Martine Zimmermann to its Board of Directors
September 26, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
September 22, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
September 21, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
September 19, 2023
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio...
Via
Benzinga
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
September 18, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 01, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
July 27, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand To Report Second Quarter 2023 Financial Results On August 8
July 25, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.